Royal Bank of Canada Grows Stock Holdings in Grifols, S.A. $GRFS

Royal Bank of Canada lifted its holdings in Grifols, S.A. (NASDAQ:GRFS) by 15.4% during the first quarter, Holdings Channel reports. The fund owned 785,703 shares of the biotechnology company’s stock after buying an additional 104,850 shares during the quarter. Royal Bank of Canada’s holdings in Grifols were worth $6,301,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in GRFS. Mirae Asset Global Investments Co. Ltd. lifted its position in Grifols by 25.7% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,928 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 1,212 shares during the period. PNC Financial Services Group Inc. boosted its holdings in Grifols by 50.3% in the first quarter. PNC Financial Services Group Inc. now owns 8,961 shares of the biotechnology company’s stock valued at $72,000 after purchasing an additional 2,998 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in Grifols by 127.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 8,219 shares of the biotechnology company’s stock worth $74,000 after purchasing an additional 4,604 shares during the period. Allworth Financial LP grew its position in Grifols by 15.7% during the 4th quarter. Allworth Financial LP now owns 8,073 shares of the biotechnology company’s stock worth $75,000 after purchasing an additional 1,096 shares during the period. Finally, Ameriprise Financial Inc. purchased a new position in shares of Grifols during the 2nd quarter valued at about $95,000.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Wall Street Zen cut Grifols from a “buy” rating to a “hold” rating in a report on Monday, May 18th. Zacks Research raised Grifols from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 7th. Finally, Weiss Ratings cut Grifols from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, July 31st. Two research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Grifols currently has an average rating of “Reduce” and a consensus price target of $10.00.

Grifols Trading Down 0.7%

Shares of Grifols stock opened at $7.99 on Wednesday. The firm has a 50-day simple moving average of $7.52 and a two-hundred day simple moving average of $8.12. The company has a market cap of $5.44 billion, a P/E ratio of 42.05, a price-to-earnings-growth ratio of 0.29 and a beta of 0.67. Grifols, S.A. has a fifty-two week low of $6.96 and a fifty-two week high of $10.84. The company has a debt-to-equity ratio of 1.10, a quick ratio of 0.81 and a current ratio of 2.37.

Grifols Dividend Announcement

The firm also recently declared a special dividend, which was paid on Thursday, July 9th. Investors of record on Thursday, July 2nd were paid a $0.0945 dividend. The ex-dividend date was Thursday, July 2nd. Grifols’s payout ratio is currently 121.05%.

Grifols Company Profile

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.